SVA Stock Overview
Operates as a clinical-stage regenerative medicine therapeutics company in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sernova Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.22 |
| 52 Week High | CA$0.73 |
| 52 Week Low | CA$0.20 |
| Beta | 1.23 |
| 1 Month Change | -4.35% |
| 3 Month Change | -10.20% |
| 1 Year Change | -68.57% |
| 3 Year Change | -88.42% |
| 5 Year Change | 29.41% |
| Change since IPO | -93.89% |
Recent News & Updates
Recent updates
Companies Like Sernova (TSE:SVA) Are In A Position To Invest In Growth
Jan 10
We're Keeping An Eye On Sernova's (TSE:SVA) Cash Burn Rate
Sep 01We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth
May 03We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth
Sep 27Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation
Feb 23We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth
Aug 11Shareholder Returns
| SVA | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -4.3% | -0.4% | -0.7% |
| 1Y | -68.6% | 12.5% | 16.3% |
Return vs Industry: SVA underperformed the Canadian Biotechs industry which returned 10.6% over the past year.
Return vs Market: SVA underperformed the Canadian Market which returned 15.9% over the past year.
Price Volatility
| SVA volatility | |
|---|---|
| SVA Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 13.5% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: SVA has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: SVA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Jonathan M. Rigby | www.sernova.com |
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs.
Sernova Corp. Fundamentals Summary
| SVA fundamental statistics | |
|---|---|
| Market cap | CA$71.57m |
| Earnings (TTM) | -CA$32.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs SVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVA income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$32.19m |
| Earnings | -CA$32.19m |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.099 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 23:59 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sernova Corp. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Orquera | First Berlin Equity Research GmbH |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Chelsea Stellick | iA Capital Markets |